The Fasting Rabbit Hole

The practical pages in this section cover what most people need to put fasting to use: what fasting is, when to do it, what protocols suit what goals, the detailed reference for specific protocols, and the metabolic state of ketosis. The Rabbit Hole is for the deeper material. Extended treatments of specific research areas, the historical and cultural dimensions, the contested frontiers, and the topics that don’t quite fit the practical pages, but warrant attention.

This is a working collection rather than a finished section. Some entries are developed treatments; others are placeholders for essays queued for development. The architecture is thematic rather than flat: each cluster groups related material, so the structure of the field is visible.

If a topic here particularly interests you, that’s useful to know. The order in which things get developed depends partly on what readers want most.

Autophagy Deep Dive

Autophagy showed up substantially in Fasting Basics because it’s foundational to the fasting story. The deeper treatment of the molecular machinery, the measurement problem, the various forms of autophagy, and the broader research landscape live here.

The Ohsumi story in more depth: Yoshinori Ohsumi began studying autophagy in yeast in the 1980s at the University of Tokyo, when the field was small enough that he could choose between competing problems and pick one no one else was working on. His early observation: yeast cells starved of nutrients formed strange membrane-bound structures in their vacuoles that nobody had previously characterised. The structures turned out to be autophagosomes: the double-membrane vesicles that engulf cellular debris for delivery to the lysosome (or vacuole in yeast).

Through the 1990s, Ohsumi’s group identified the ATG (autophagy-related) genes by systematically screening yeast mutants for those that couldn’t perform autophagy. By the late 1990s, they’d identified roughly 15 ATG genes, eventually expanding to over 40. Many of the mammalian equivalents were subsequently identified, establishing autophagy as evolutionarily conserved from yeast through humans.

The 2016 Nobel Prize in Physiology or Medicine was awarded to Ohsumi alone, which was unusual for the field (most Nobels in biology go to 2-3 researchers). The committee’s reasoning: Ohsumi’s foundational work was so central to the field’s emergence that it justified single-recipient recognition.

The molecular machinery: Modern understanding of autophagy involves several key components:

• The ULK1 complex: the kinase complex that initiates autophagy in response to nutrient signals. Inhibited by mTOR (which signals nutrient sufficiency); activated by AMPK (which signals energy depletion).
• The PI3K-III complex: produces phosphatidylinositol 3-phosphate, which marks the autophagosome membrane for protein recruitment.
• The LC3/Atg8 system: proteins that mark cargo for autophagy and conjugate to the autophagosome membrane during formation.
• The Atg12-Atg5-Atg16L1 system: involved in autophagosome formation.
• p62/SQSTM1: the adaptor protein that links ubiquitinated cargo to LC3 for selective autophagy.

These are the proteins that show up in autophagy research papers and that pharmaceutical interventions target. This is not a simple “on/off” switch but a multi-component machine with substantial regulation.

The human measurement problem: Worth understanding why we know less about human autophagy than mouse autophagy. Direct autophagy measurement in living humans is technically difficult. The standard methods (LC3 conversion in tissue, p62 levels, autophagosome counting by electron microscopy) require tissue samples. Most human research uses indirect markers (blood-based proxies that don’t directly measure autophagy in the tissue of interest) or autopsy/biopsy tissue from specific clinical contexts.

The “autophagy kicks in at 16 hours” or “peak autophagy at 48-72 hours” claims that circulate in the popular literature are extrapolated primarily from:

• Mouse studies where tissue autophagy can be directly measured
• Cell culture studies where the conditions are simplified
• Limited human studies using indirect markers
• Theoretical scaling based on metabolic rates

Fasting upregulates autophagy in humans. The specific timing of when it “kicks in” is less precisely characterised than the popular literature implies. The peer-reviewed research is genuinely less clean than the practitioner literature suggests.

Mitophagy specifically: A specialised form of autophagy that selectively degrades damaged mitochondria. Mitophagy is particularly important because mitochondrial damage accumulates with age and contributes to declining cellular function. The PINK1/Parkin pathway is the most-studied mitophagy mechanism; mutations in these genes are associated with early-onset Parkinson’s disease, suggesting that defective mitophagy contributes to neurodegeneration. Exercise upregulates mitophagy in working muscle; fasting upregulates it more broadly.

Chaperone-mediated autophagy (CMA): Distinct from macroautophagy (the standard process). CMA involves a chaperone protein (HSC70) recognising a specific amino acid sequence on target proteins, escorting them to the lysosome through a specific membrane translocation, and unfolding them for degradation. Ana Maria Cuervo’s group at Einstein has done much of the foundational CMA work. CMA decreases substantially with age, and the decline contributes to the accumulation of damaged proteins in older tissues. Caloric restriction and fasting upregulate CMA in addition to macroautophagy.

Spermidine and autophagy: Spermidine is a polyamine compound that pharmacologically induces autophagy without requiring fasting. Frank Madeo’s group at Graz has done substantial work on spermidine as a caloric restriction mimetic. Dietary sources include aged cheese, mushrooms, soybeans, and wheat germ. Spermidine supplementation has shown some longevity-extending effects in mice and observational benefits in epidemiological studies. Clinical trials are emerging but are limited. The mechanism appears to involve histone hypoacetylation that mimics the gene expression changes of caloric restriction.

The “more autophagy is always better” framing is too simple: This deserves direct treatment because it’s a common confusion. Autophagy in the right tissues at the right time is beneficial. Excessive autophagy can contribute to disease; some forms of muscle wasting involve excessive autophagy, and chronic excessive autophagy can produce cellular dysfunction. The body has substantial regulation around autophagy precisely because the process needs to be calibrated rather than maximised.

• For practical fasting purposes, this nuance matters less because dietary fasting doesn’t push autophagy into pathological ranges in healthy adults. But the simple narrative of “more autophagy = more longevity = always good” doesn’t quite match the biology.

Future essays in this cluster:

• The mTOR/AMPK seesaw is the master regulator of growth vs maintenance
• Pharmacological autophagy induction (rapamycin, spermidine, others) compared with fasting-induced autophagy
• Cancer and autophagy: the double-edged sword (autophagy suppresses early tumour formation but protects established tumours)
• Neurodegeneration and autophagy: the case for proteostasis-as-cause

The Longo Lab Body of Work

Valter Longo’s group at USC’s Longevity Institute has produced one of the most consistent and high-impact bodies of research on fasting over the past two decades. The work has touched on longevity mechanisms, fasting protocols, immune regeneration, chemotherapy protection, and several specific disease applications.

The IGF-1 longevity story: Longo’s foundational work began with simple model organisms (yeast and mice with mutations in the IGF-1 signalling pathway). The pattern: reducing IGF-1 signalling extended lifespan substantially. The mechanism appeared to involve reduced cellular damage accumulation, improved stress resistance, and reduced cancer risk (IGF-1 is a major growth signal that, chronically elevated, supports both healthy tissue and tumour growth).

The human translation: protein restriction (which lowers IGF-1) and fasting (which substantially lowers IGF-1 during the fasting period) both reduce one of the major pro-ageing signalling pathways. Longo’s Cell Metabolism 2014 paper found that adults aged 50-65 with high protein intake had a 4-fold increased risk of cancer mortality compared with those with low protein intake, with intermediate intake producing intermediate risk. The relationship reversed in adults over 65, where higher protein intake was protective (consistent with the sarcopenia and protein needs of older adults).

The implication: optimal protein intake is age-dependent. Younger and middle-aged adults may benefit from moderate protein with periodic protein restriction or fasting; older adults need higher protein to maintain muscle. The framework’s protein guidance across Nutrition and The Longevity Program reflects this nuance.

The Fasting Mimicking Diet development: Longo developed the FMD as a way to make prolonged fasting safer, more tolerable, and more clinically usable. Pure water fasting for 5+ days produces substantial therapeutic effects but isn’t appropriate for most clinical populations. The FMD provides enough calories and nutrients to be safer while still maintaining the metabolic signatures of fasting.

Brandhorst et al. 2015 Cell Metabolism established the protocol in mice and presented initial human data. Wei et al. 2017 Science Translational Medicine presented the pivotal human trial. Subsequent work has applied FMD to:

• Cardiovascular and metabolic risk reduction
• Cancer chemotherapy adjuvant (protecting healthy cells while sensitising cancer cells)
• Multiple sclerosis (Choi et al. 2016 Cell Reports showed FMD reducing demyelination and improving symptoms in mouse models)
• Type 2 diabetes
• Autoimmune conditions

Stem cell regeneration: Cheng et al. 2014 Cell Stem Cell identified the mechanism by which prolonged fasting triggers stem cell regeneration in mice and humans. The pathway involves PKA suppression during fasting, which removes inhibition on hematopoietic stem cell self-renewal. Refeeding then triggers proliferation and differentiation. The result is a measurably “younger” immune cell population after the cycle completes.

• This is the foundational mechanism behind the “fasting resets your immune system” claims. The effect is real; the specific tissues involved (hematopoietic stem cells producing blood and immune cells) are well-characterised. Whether similar mechanisms operate in other stem cell populations (gut, muscle, neural) is the subject of active research.

Chemotherapy protection: A particularly elegant body of work from the Longo group: fasting before and during chemotherapy can protect healthy cells while sensitising cancer cells to treatment. The mechanism involves the “differential stress resistance” effect. Healthy cells respond to fasting by entering a protective state that reduces sensitivity to cytotoxic drugs, while cancer cells (which have lost normal regulatory mechanisms) can’t enter the protective state and remain vulnerable.

• Multiple clinical trials have shown FMD or short-term fasting before chemotherapy reduces side effects and may improve treatment response. The protocols are increasingly being adopted in clinical oncology, though they remain off-label and require oncologist supervision.

Commercial dimension: Longo founded L-Nutra, which sells ProLon (the packaged FMD product). The commercial relationship is real and warrants noting; the underlying science is also real and has been replicated by independent groups. The combination is common in biomedical research, where the researcher who developed an intervention also commercialises it. The science is what it is; readers can evaluate the commercial dimension separately.

Future essays in this cluster:

• The differential stress resistance mechanism in detail
• The multiple sclerosis trial and the broader autoimmune implications
• The Longo dietary recommendations (the Longevity Diet): synthesis and critique
• The IGF-1 longevity story across model organisms

The Panda Lab Body of Work

Satchidananda Panda’s group at the Salk Institute has been the major force behind the time-restricted eating research. The work has demonstrated that the way you eat affects metabolic outcomes independently of what and how much you eat.

The foundational mouse work: Hatori et al. 2012 Cell Metabolism compared mice given the same total calories of the same high-fat diet, with one group eating ad libitum across 24 hours and the other restricted to 8-hour windows. The time-restricted mice were leaner, had better insulin sensitivity, lower inflammation, lower cholesterol, and lived longer. The total caloric intake was the same. The difference was timing.

This finding was so striking that it generated substantial follow-up work establishing the boundary conditions: how long does the eating window need to be, when in the circadian cycle does it need to fall, what happens when the protocol breaks on weekends, and what role do specific genes play in mediating the effect.

The circadian alignment principle: The mechanism Panda’s group articulated: the body’s metabolic and cellular machinery operates on circadian cycles, with different processes upregulated at different times of day. Liver gene expression alone shows roughly 20% of genes cycling on a 24-hour rhythm. Gut microbiome composition cycles. Hormonal patterns cycle. The whole system anticipates a feeding-fasting cycle aligned with the light-dark cycle.

Eating outside the expected feeding window (particularly late at night) disrupts this alignment, producing what Panda calls “circadian disruption”: a state where different organs and tissues are receiving conflicting timing signals. The disruption produces metabolic dysfunction over time, even when total caloric intake is matched.

The human translation challenges: Mouse-to-human translation is harder for time-restricted eating than for some other interventions because:

• Mouse circadian rhythms run on shorter cycles than human rhythms in some respects
• Mouse activity patterns differ substantially from human patterns
• The mouse studies use very small eating windows (8 hours) for translation to humans, where the practical bar is often 10-12 hours
• Human studies are subject to confounding by what people actually eat during eating windows

Despite these challenges, human TRE research has been consistent in showing benefits, though the effects are typically more modest than the mouse studies suggest.

The Sutton/Peterson 2018 trial: A small but elegant trial from the Pennington Biomedical Research Center using “early time-restricted feeding” (eTRF): an 18-hour fast with a 6-hour eating window ending before 3 PM. The trial controlled for total caloric intake (the same calories were consumed in both arms, just at different times). Results: substantial improvements in insulin sensitivity, blood pressure, oxidative stress, and appetite control in the eTRF arm even without weight loss.

• Timing of eating matters independently of how much you eat. The earlier eating window appears to be the most effective placement, aligning with the body’s natural metabolic rhythms.

The Wilkinson 2020 metabolic syndrome trial: Wilkinson et al. 2020 Cell Metabolism tested 10-hour TRE in adults with metabolic syndrome. Results: significant reductions in body weight, blood pressure, and atherogenic lipids over 12 weeks. The protocol was less restrictive than the Sutton/Peterson eTRF (10 hours instead of 6), making it more accessible for general population use.

The TREAT trial complication: Lowe et al. 2020 JAMA Internal Medicine (the TREAT trial at UCSF) compared 16:8 TRE with normal eating across 12 weeks in overweight adults. Results: no significant difference in weight loss between groups. The trial complicated the simpler “TRE causes weight loss” narrative and prompted substantial discussion in the field.

• The likely explanations: the trial used late-window TRE (eating window starting at noon, ending at 8 PM, which doesn’t optimally align with circadian rhythms), the trial allowed unlimited caloric intake during the eating window (so participants may have compensated by eating more), and 12 weeks may have been too short to capture the longer-term metabolic effects.
• The TREAT trial doesn’t refute the broader TRE literature, but it does complicate the picture. TRE works when implemented well; suboptimal implementation produces suboptimal results. The Sutton/Peterson early-TRF protocol and the Wilkinson 10-hour window appear to produce stronger effects than late-TRF approaches.

Future essays in this cluster:

• The circadian gene expression cycling in detail
• Optimal eating window placement (early vs late TRE)
• The gut microbiome’s circadian cycling and its relationship to host eating patterns
• The TREAT trial post-mortem and what it tells us about implementation

Cancer Metabolism Deep Dive

Cancer metabolism deserves substantial treatment because it’s one of the most active research areas at the intersection of fasting and disease, and because the popular discussions often oversimplify in either direction (dismissing the metabolic theory entirely or treating the ketogenic diet as an established cancer cure).

Otto Warburg’s foundational work: In the 1920s, the German biochemist Otto Warburg observed that cancer cells preferentially use glycolysis (the inefficient anaerobic glucose pathway) even in the presence of oxygen. A state now called the “Warburg effect.” Healthy cells with adequate oxygen prefer oxidative phosphorylation (the much more efficient mitochondrial pathway). Cancer cells appeared to have lost this preference, producing energy through glycolysis even when oxidative phosphorylation should be possible.

Warburg proposed that this metabolic shift wasn’t incidental to cancer but central to it, that mitochondrial dysfunction was the underlying cause of cancer, with the genetic mutations of cancer being downstream consequences. The view was contested in his lifetime and largely dismissed through the 20th century in favour of the gene-centric view (cancer as primarily a disease of accumulated genetic mutations driving uncontrolled growth). Warburg died in 1970 with his theory considered an interesting historical artifact.

Seyfried’s revival of the metabolic theory: Thomas Seyfried at Boston College has been the most visible academic voice articulating a modern version of Warburg’s theory. Cancer as a Metabolic Disease (2012) presents the case in detail; the press-pulse therapeutic strategy paper (Seyfried et al. 2017) articulates the clinical implications.

The modern metabolic theory of cancer:

• Cancer cells have damaged mitochondria, leading to reliance on glycolysis
• The genetic mutations seen in cancer are largely downstream of this mitochondrial damage
• Restoring metabolic function or denying glycolytic fuel could treat cancer
• The cancer cell’s dependence on glucose (and glutamine) for glycolytic fuel makes it vulnerable to interventions that restrict these substrates
• Healthy cells can switch to ketone metabolism; cancer cells largely can’t

Most contemporary cancer researchers would acknowledge that metabolic dysfunction is present in cancer; the question is whether it’s causal or downstream.

The press-pulse protocol: Seyfried’s articulated therapeutic strategy combines:

• Press: sustained metabolic stress on cancer cells through ketogenic diet (denying glucose), caloric restriction, and hyperbaric oxygen therapy (which damages cancer cells but not healthy cells because cancer cells lack functional mitochondria to handle the oxygen properly)
• Pulse: acute interventions including drugs that target glucose metabolism (2-deoxyglucose, 3-bromopyruvate), glutamine antagonists, and standard chemotherapy

The protocol has been used in case studies and small clinical series with some dramatic responses. The clinical evidence is sufficient to take seriously, but insufficient to establish the protocol as standard of care.

Current clinical state: Multiple clinical trials are evaluating the ketogenic diet as an adjuvant to standard cancer treatment. The early results suggest:

• Ketogenic diet improves tolerance of chemotherapy and radiation (less nausea, less fatigue, better quality of life)
• Ketogenic diet may enhance treatment effectiveness for certain cancers (glioblastoma has been a particular focus)
• The combination of FMD with chemotherapy (the Longo approach, mechanistically related but distinct from Seyfried’s continuous ketogenic protocol) is being adopted in some oncology practices
• The evidence for the ketogenic diet as a standalone cancer treatment is much weaker than the evidence for it as an adjuvant

Glioblastoma as the most-studied application: Glioblastoma is an aggressive brain cancer with a poor prognosis under standard treatment. Several characteristics make it particularly amenable to metabolic intervention:

• The brain depends heavily on glucose under normal conditions
• Glioblastoma cells are particularly glucose-dependent
• Healthy brain tissue adapts well to ketone metabolism
• The blood-brain barrier limits some chemotherapy effectiveness, making metabolic interventions relatively more valuable

Case reports and small clinical series have documented dramatic responses in some glioblastoma patients on ketogenic + standard treatment protocols. Larger trials are underway. The picture is genuinely promising but not yet conclusive.

Future essays in this cluster:

• The Warburg effect in detail and the modern molecular understanding
• Glutamine as the second metabolic vulnerability of cancer cells
• The specific clinical trials underway and their early results
• The intersection of fasting protocols (Longo) and continuous ketogenic eating (Seyfried)
• The metabolic mechanism behind chemotherapy protection during fasting

Therapeutic Fasting for Metabolic Disease

Type 2 diabetes, obesity, metabolic syndrome, fatty liver disease, and PCOS. The mechanisms are well-understood (these are diseases of insulin resistance and metabolic inflexibility; fasting directly addresses both), and the clinical results are often dramatic.

Jason Fung’s clinical work: Jason Fung is a Toronto-based nephrologist who developed an intensive dietary management program for diabetes and obesity, using extended fasting protocols as the primary intervention. His clinical experience and published case series demonstrate that type 2 diabetes (long considered a chronic progressive disease) can be reversed in many patients through structured fasting protocols.

The Furmli et al. 2018 BMJ Case Reports publication documented three patients with type 2 diabetes who used intermittent fasting (24-72 hour fasts 2-3 times per week) and were able to discontinue insulin therapy within weeks while maintaining normal blood glucose. Subsequent case series have shown similar results.

Fung is a clinician-populariser rather than primarily an academic researcher. His books (The Obesity Code, The Complete Guide to Fasting) translate the science for general audiences and present clinical protocols accessible to non-specialists. His clinical experience with diabetes reversal is substantial. The commercial dimension (he runs the Intensive Dietary Management program commercially) warrants noting; the clinical results are real.

The mechanistic case for why fasting works for T2D:

• Type 2 diabetes is fundamentally a state of insulin resistance with hyperinsulinemia
• The conventional treatment (medications to lower blood glucose, including insulin) addresses the symptom (high blood glucose) while exacerbating the cause (already-elevated insulin)
• Fasting directly addresses the cause: by removing the dietary trigger for insulin secretion, insulin levels fall, and the insulin resistance gradually resolves
• The body’s own regulatory mechanisms recover their function when not constantly overstimulated

This isn’t controversial mechanistically; it’s why caloric restriction and ketogenic diets also work for T2D. Fasting is one of several interventions that address the underlying cause rather than the surface symptom.

Virta Health’s clinical model: Sarah Hallberg’s work with Virta Health uses a ketogenic diet rather than fasting, with continuous remote care. The 2-year data published in Frontiers in Endocrinology showed 53% of patients achieving full T2D remission (defined as HbA1c below diabetic range without medication), with another portion achieving partial remission or substantial medication reduction. The clinical model integrates physician supervision, continuous glucose monitoring, dietary coaching, and community support.

The Virta approach represents one of the most rigorous clinical implementations of metabolic intervention for T2D. Multiple subsequent trials have replicated similar effects. The state of evidence is clear: type 2 diabetes is reversible in many cases through dietary intervention.

The broader clinical fasting movement: The renewed clinical interest in fasting traces partly to Fung’s work, partly to Longo’s FMD research, partly to the rediscovery of pre-pharmaceutical-era therapeutic fasting practices (Joel Fuhrman, Alan Goldhamer, and the broader water fasting clinic tradition that survived in some practitioner communities through the 20th century).

The clinical applications now being investigated:

• T2D reversal (most evidence)
• Metabolic syndrome
• PCOS
• Fatty liver disease
• Hypertension
• Migraine
• Inflammatory bowel disease
• Rheumatoid arthritis and other autoimmune conditions
• Some psychiatric conditions (Palmer’s metabolic psychiatry work, covered in Ketosis)

Future essays in this cluster:

• The clinical implementation of T2D reversal protocols
• The autoimmune applications and emerging evidence
• The water fasting clinic tradition (TrueNorth Health Center and others)
• The intersection of fasting and bariatric surgery outcomes

Caloric Restriction Mimetics

A category of substances that activate fasting-like or caloric-restriction-like pathways without requiring fasting or caloric restriction.

Rapamycin: The pharmaceutical that directly inhibits mTOR, mimicking the effect of severe caloric restriction or extended fasting. Originally developed as an immunosuppressant for organ transplant recipients; subsequently discovered to extend lifespan in multiple model organisms (yeast, worms, flies, mice). Currently being studied for human longevity applications.

• The evidence in mice is among the strongest for any longevity intervention: rapamycin extends mouse lifespan by roughly 10-20% even when started in middle age, and it improves multiple healthspan markers. The human translation is uncertain but actively investigated. Some longevity-focused practitioners prescribe rapamycin off-label for healthspan purposes; the FDA hasn’t approved it for this use, and the long-term safety data in healthy humans is limited.
• Mechanism: rapamycin directly inhibits mTOR Complex 1 (mTORC1), the master regulator of cell growth. By suppressing mTOR, rapamycin produces many of the cellular effects of fasting (autophagy upregulation, reduced protein synthesis, shifted gene expression) without requiring food deprivation. The shift from “growth” to “maintenance” cellular state appears to be a major contributor to its longevity effects.

Metformin: The oldest and most-prescribed type 2 diabetes medication. Acts primarily by activating AMPK (the cellular energy sensor) and reducing hepatic glucose production. Mimics some of the metabolic effects of caloric restriction.

• The longevity interest: metformin appears to reduce all-cause mortality in diabetic patients to levels at or below those of non-diabetic controls. A striking finding that suggests it may have benefits beyond diabetes control. The TAME (Targeting Aging with Metformin) trial is designed to test whether metformin extends healthspan in non-diabetic adults; results are expected over the coming years.
• The mechanism overlap with fasting: AMPK activation, mild mitochondrial complex I inhibition (which produces a mild “energy stress” that activates protective pathways), and effects on the gut microbiome.

Resveratrol: The polyphenol from grape skins that became famous in the 2000s for its purported sirtuin-activating, longevity-promoting effects. The David Sinclair lab at Harvard was the major academic source of resveratrol research, and Sinclair’s commercial interests (Sirtris Pharmaceuticals, sold to GlaxoSmithKline for $720 million in 2008) made the substance commercially substantial.

• The actual evidence has been more equivocal than the initial enthusiasm suggested. Some studies show benefits, others don’t. The bioavailability of oral resveratrol is poor. The doses used in animal studies are difficult to achieve in humans. The current academic consensus is that resveratrol has some interesting properties but isn’t the “fountain of youth” that the early commercial framing suggested.

Spermidine: Polyamine compound that pharmacologically induces autophagy. Madeo’s research group has been the major source of spermidine longevity research. Dietary sources include aged cheese, mushrooms, soybeans, and wheat germ. Some clinical evidence suggests spermidine supplementation may produce benefits, though the human clinical trial base is still developing.

NMN and NR (NAD+ precursors): Sinclair’s lab has been substantially involved in NAD+ research as well. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that the body can convert to NAD+. NAD+ declines with age, and the decline is implicated in mitochondrial dysfunction and reduced sirtuin activity.

• Supplementation with NAD+ precursors has shown some benefits in animal studies. Human clinical evidence is mixed and limited. The commercial supplement industry around NMN/NR has substantially outpaced the clinical evidence. Sinclair’s personal commercial interests in NAD+ supplementation companies warrant noting. The actual mechanism question, whether oral NAD+ precursors reach the tissues where they’re needed, is still being investigated.

Caloric restriction mimetics vs actual caloric restriction: The pharmacological mimetics activate some of the pathways that fasting activates, but don’t reproduce the full effect. Actual fasting:

• Activates AMPK (via energy depletion)
• Inhibits mTOR (via nutrient depletion)
• Upregulates sirtuins (via NAD+ elevation)
• Produces ketone bodies (with all the signalling effects of BHB)
• Induces autophagy
• Reduces IGF-1
• Activates immune cell turnover
• Improves insulin sensitivity
• Reduces inflammation

A pharmacological intervention typically activates one or two of these pathways. Rapamycin substantially activates the mTOR/autophagy axis. Metformin activates AMPK. Spermidine activates autophagy. None of them fully reproduces what fasting does. The evidence suggests caloric restriction mimetics produce a fraction of the benefit of actual caloric restriction or fasting, with the practical advantage that they can be sustained continuously, where fasting cannot.

Caloric restriction mimetics are a legitimate research area with real but limited applications. They’re not equivalent to fasting. The commercial extrapolation around several of them (resveratrol, NAD+ precursors) has exceeded the evidence base substantially. For most people, actual fasting practice produces more reliable benefits than supplement-based mimetics.

Future essays in this cluster:

• Rapamycin for healthspan: the state of the evidence
• The TAME trial and what we might learn from metformin
• The Sinclair commercial dimension and how it complicates the longevity supplement landscape
• Stacking interventions: do they add or interfere?

BHB as Signalling Molecule

The treatment in Ketosis covered the basics; this is the deeper treatment of BHB’s signalling roles, which represent one of the more interesting recent additions to the field.

The Newman & Verdin framework: Eric Verdin (Buck Institute) and John Newman (UCSF) have done much of the foundational work establishing BHB as more than a fuel substrate. Their 2014 Trends in Endocrinology & Metabolism review consolidated the case that BHB acts as a signalling molecule with effects on gene expression, inflammation, and cellular function.

HDAC inhibition: BHB inhibits class I histone deacetylases (HDAC1, HDAC2, HDAC3). HDACs are enzymes that remove acetyl groups from histones (the proteins around which DNA winds), generally reducing gene expression. HDAC inhibition, therefore, produces a state of increased gene expression at the targeted genes.

The genes that get upregulated by BHB-mediated HDAC inhibition include several involved in oxidative stress resistance: FOXO3A (a major longevity-associated transcription factor), MT2 (metallothionein 2, involved in metal binding and antioxidant defence), and several mitochondrial genes. The effect: cells exposed to BHB become more resistant to oxidative damage. This is part of why ketogenic diets and fasting produce neuroprotection beyond what fuel substitution alone would explain.

The NLRP3 inflammasome inhibition: The NLRP3 inflammasome is a major pro-inflammatory protein complex that activates in response to various cellular stresses (damaged organelles, cholesterol crystals, uric acid crystals, certain microbial signals). Once activated, NLRP3 triggers the production of IL-1β and IL-18, two major pro-inflammatory cytokines.

NLRP3 inflammasome activation is implicated in:

• Atherosclerosis
• Type 2 diabetes
• Gout
• Alzheimer’s disease
• Several autoimmune conditions

BHB directly inhibits NLRP3 activation. The mechanism appears to involve BHB binding to a specific site on the NLRP3 complex, preventing the conformational change required for activation. The effect: substantially reduced inflammation during ketosis, beyond what reduced caloric intake alone would produce.

This is part of why ketogenic eating produces dramatic improvements in inflammatory conditions like rheumatoid arthritis, gout, and certain skin conditions. The mechanism specifically involves BHB rather than the absence of carbohydrates per se.

GPR109A activation: BHB acts as an agonist for HCAR2 (also called GPR109A), a G-protein-coupled receptor on immune cells, fat cells, and certain other tissues. The same receptor is activated by niacin (vitamin B3) and by butyrate (the short-chain fatty acid produced by gut bacteria fermenting fibre).

GPR109A activation produces:

• Reduced lipolysis in adipose tissue (paradoxical given fasting context; appears to be a negative feedback mechanism)
• Anti-inflammatory effects in immune cells
• Reduced atherosclerotic plaque formation
• Various effects on lipid metabolism

The convergence of BHB, niacin, and butyrate on the same receptor is interesting: it suggests an evolutionarily conserved signalling pathway for “energy substrate” molecules that the body uses to coordinate metabolism and inflammation.

Direct neuroprotection: BHB appears to have direct protective effects on neurons exposed to oxidative or metabolic stress, beyond the fuel-provision and HDAC-inhibition effects. The mechanism may involve mitochondrial protection, reduced ROS production, and effects on apoptotic pathways. The clinical implication: BHB may be neuroprotective in conditions like Alzheimer’s, Parkinson’s, and traumatic brain injury, in ways that distinguish it from simple “alternative fuel” effects.

The exogenous ketone supplementation question: Given BHB’s signalling roles, the obvious question is whether supplementing exogenous BHB produces the same effects as endogenous BHB. The early enthusiasm for exogenous ketone supplements (ketone salts, ketone esters) was substantial; the supplement industry around them has grown rapidly.

The evidence is mixed:

• Exogenous ketones do raise blood BHB levels reliably
• The duration of elevation is shorter than with endogenous production (typically 1-3 hours per dose)
• Whether the BHB elevation produces the full range of signalling effects is uncertain
• The metabolic state of the body matters: exogenous BHB in a fed, glucose-elevated state may behave differently than endogenous BHB in a fasted state
• The cost of meaningful supplementation is substantial ($5-20+ per dose for ester products)
• Side effects (GI distress, electrolyte effects) are common with ketone salts

Exogenous ketones are a legitimate research area with some clinical applications (acute brain protection, certain athletic contexts, possibly some neurological conditions). They’re not a substitute for actual ketogenic eating or fasting for most longevity and metabolic applications. The supplement marketing has substantially exceeded the clinical evidence.

Future essays in this cluster:

• The detailed mechanism of HDAC inhibition by BHB
• The NLRP3 inflammasome and its role across diseases
• Exogenous ketone esters vs ketone salts: clinical applications
• The “metabolic switching” hypothesis and BHB’s role in adaptive cellular responses

The Religious and Cultural History of Fasting

Why have so many independent cultures across thousands of years arrived at fasting practices? The variety of explanatory frameworks is enormous; the underlying practice is remarkably consistent.

Islamic fasting: Ramadan is observed by roughly two billion Muslims annually, making it the most widely practised fast in the world. Throughout the lunar month of Ramadan, observant Muslims abstain from food and drink (including water) from dawn to sunset, breaking the fast each evening (iftar) and consuming a pre-dawn meal (suhur). The fasting period varies from roughly 11 to 19 hours depending on latitude and season.

• Beyond Ramadan, Islamic tradition includes additional voluntary fasts: Mondays and Thursdays, the middle three days of each lunar month, the day of Ashura, the day of Arafah, and the six days of Shawwal following Ramadan. Observant practitioners may fast 100+ days per year through these voluntary practices.
• The Ramadan literature is the largest natural experiment in periodic fasting in the world, with substantial research on metabolic, cognitive, and health effects in observing populations. Outcomes vary; adverse events are rare in healthy adults observing properly.

Christian fasting: Christian traditions vary enormously in their fasting practices. Eastern Orthodox Christianity has the most rigorous calendar: roughly 180 days per year of fasting if observing the full liturgical calendar, with Great Lent (40 days before Easter), Advent (40 days before Christmas), the Apostles’ Fast, the Dormition Fast, plus weekly fasting on Wednesdays and Fridays. The Orthodox version of fasting typically allows two small meals per day with abstention from animal products rather than total food abstention.

• Roman Catholic fasting has historically been substantial (40-day Lent with various levels of restriction, plus weekly Friday abstinence) but has been substantially relaxed since the Second Vatican Council in the 1960s.
• Protestant traditions vary widely; many have minimal formal fasting practices, though periodic fasting is common in some Evangelical traditions for spiritual purposes.

Jewish fasting: Yom Kippur is the most stringent fast, involving 25 hours of complete abstention from food and water (along with other prohibitions). Tisha B’Av is another 25-hour complete fast. Several other days involve dawn-to-dusk fasts: the Fast of Gedalia, the Tenth of Tevet, the Seventeenth of Tammuz, and the Fast of Esther. Voluntary fasts (taanit) on the anniversary of a parent’s death and for various other purposes have been historically common.

Hindu fasting: Substantial variety across regional and sectarian traditions. Ekadashi (the 11th day of each lunar fortnight) is a widely observed fast among many Hindus, occurring approximately twice per month. The fast typically involves abstention from grains, beans, and certain other foods rather than total fasting; some practitioners observe complete fasts. Navratri (nine nights twice per year), Karva Chauth (married women fasting for their husband’s longevity), and numerous other festival fasts add to the calendar.

• Some renunciate traditions (sadhus, sannyasis) involve substantially more intensive fasting practices, including extended fasts as spiritual discipline.

Buddhist fasting: Theravada Buddhist monks and nuns traditionally don’t eat after midday, the “no eating after noon” rule that produces an approximately 18-hour daily fast. This practice has been continuous from the time of the Buddha (roughly 2,500 years ago) and is still observed by monastic communities throughout South and Southeast Asia.

• Some Mahayana traditions include more substantial fasting practices, including extended retreats with restricted eating. The Japanese Buddhist practice of sōkushinbutsu (self-mummification through extreme dietary restriction culminating in death) represents the extreme end of religious fasting traditions, though it was banned in the 19th century.

Jain fasting: Jain traditions include some of the most rigorous fasting practices of any major religion. Paryushan (8-10 days of intensive religious observance) typically involves extensive fasting. Some Jain monastics practice complete fasts (santhara) at the end of life as a spiritual practice. The Jain rejection of harm to any living being extends to fasting practices that minimise consumption.

Indigenous and traditional practices. Across the Americas, Africa, Asia, and Oceania, indigenous traditions have included substantial fasting practices:

• Vision quests in many Native American traditions, involving multi-day fasts often combined with isolation in nature
• Coming-of-age fasts in numerous cultures
• Seasonal restriction practices tied to food availability cycles
• Ceremonial fasts for healing, divination, or spiritual purposes

The underlying question… Why has fasting recurred independently across so many cultures? Several non-exclusive explanations:

1. Pragmatic origin: Food scarcity was the historical default. Cultures developed practices that ritualised and gave meaning to the periods of scarcity that occurred regardless. The “spiritual” interpretation provided meaning for what was happening anyway.
2. Biological reinforcement: The metabolic effects of fasting (improved mental clarity, reduced anxiety, the characteristic “fasting state” cognitive shift) provided positive experiential feedback that reinforced the practices even when the cultural frameworks were different.
3. Social function: Communal fasting practices create group cohesion, mark time, demarcate sacred from ordinary periods, and provide structure for collective life.
4. Genuine spiritual or psychological effects: Whatever one’s metaphysical views, the experience of fasting produces psychological changes (altered perception, intensified concentration, mood shifts) that practitioners across traditions consistently describe as meaningful.

The convergence across unrelated cultures doesn’t prove any specific metaphysical claim; it does suggest the underlying practice is doing something. The framework’s position throughout this section has been that the biology is real, the cultural frameworks are diverse, and the recurrence of the practice across human history reflects something genuine about what humans are.

Future essays in this cluster:

• Detailed treatment of Ramadan and the substantial research literature on its health effects
• The Eastern Orthodox fasting calendar and the longevity outcomes in observant populations
• Vision quest traditions and their psychological/biological effects
• The intersection of fasting and contemplative practice across traditions

The Limits of Self-Experimentation

The fasting practice space has been substantially shaped by self-experimentation and personal experience. The biohacking community, the practitioner literature, and the popular online discussions, much of this content reflects individuals’ experiences with their own fasting practice, often presented with substantial confidence about what they’ve learned.

This is worth engaging with directly because the framework’s position throughout has been that the biology is real, but individual application is highly variable. What can individuals actually learn from their own n=1 experiments with fasting?

What individual experimentation can usefully reveal:

• Subjective response to specific protocols. Does 16:8 work for you? Do you feel better on it? Worse? You can answer this through experimentation in a way that clinical research can’t.
• Effects on energy, mood, and cognitive performance. Subjective outcomes that don’t require clinical measurement.
• Body composition changes over time. Visible and trackable with simple tools.
• Specific symptom responses. If you have migraine, IBS, or some other identifiable condition, does fasting affect your symptoms?
• Compatibility with your life. Does the protocol fit your schedule, social life, training, and work demands?
• Performance effects. Does fasted training compromise your training? Does the timing of meals affect your work performance?

People who pay attention to these things often learn substantial, useful information about their own physiology.

What individual experimentation typically can’t reveal:

• Long-term cardiovascular outcomes. Will this fasting practice extend or shorten your life? You can’t tell. The relevant outcomes manifest over decades and require populations to detect.
• Cancer risk effects. Same problem. Individual outcomes don’t reveal population-level risk effects.
• Long-term cognitive trajectory. Will your dementia risk be different at 80 because of what you’re doing now at 45? Can’t tell.
• Bone density and sarcopenia trajectory. Effects accumulate over decades.
• Hormonal effects beyond the immediately observable. Your testosterone, estrogen, thyroid, cortisol, and IGF-1 are all changing, but you can’t directly observe their trajectories.
• Microbiome effects. Changing, but not readily observable.
• Whether you’re optimising or just feeling okay while something is going wrong. This is the most insidious limitation. Many things that feel fine for years produce problems later.

The optimism bias of self-experimentation: A pattern worth flagging: People who maintain practices over time tend to be people for whom those practices work. People for whom a practice produced bad outcomes typically stopped doing it. The pool of long-term practitioners is therefore self-selected for the practice working for them.

• This produces systematic optimism in the practitioner literature: 5-year carnivore practitioners, 10-year intermittent fasters, 20-year vegans, each of these populations reports substantial positive effects from their practice, but the populations are selected for having tolerated their practice. The people who got worse usually quit.
• This isn’t unique to fasting; it applies to any sustained practice. But it matters for how to interpret the “I’ve been doing X for Y years, and it’s been transformative” reports that fill the practitioner literature. The reports are often genuine and accurate for the people making them; they don’t necessarily indicate that the practice works equally well for everyone.

The case for n=1 anyway: Despite these limitations, individual experimentation has substantial value. Clinical research averages effects across populations; the effects on you specifically are obscured by averaging. Some things that don’t show up in clinical trials matter substantially for individuals: your specific response to a protocol, your specific life context, and your specific goals.

• Pay attention to what your experiments reveal, but hold the conclusions with appropriate humility. What worked dramatically well for you for 6 months may not be what serves you over 30 years. What didn’t seem to do much for you in 6 months may have been doing something you couldn’t measure. The relationship between subjective experience and longer-term outcomes is loose.

The role of clinical research alongside self-experimentation: Neither replaces the other. Clinical research gives us the population-level patterns: who tends to benefit from what protocols, what side effects to watch for, and what mechanisms operate. Self-experimentation gives us individual application: how you specifically respond, what fits your life, and what subjective improvements you experience.

Future Topics for Development

A working list of essays queued for development as the section grows:

• The water fasting clinic tradition: TrueNorth Health Center, Alan Goldhamer’s work, and the broader naturopathic fasting tradition that survived in some practitioner communities through the 20th century. 
• Fasting and autoimmunity: The emerging research on fasting protocols for rheumatoid arthritis, multiple sclerosis, lupus, inflammatory bowel disease, and other autoimmune conditions. Mechanism, clinical evidence, practical implementation.
• Exogenous ketone esters in detail: The specific compounds, their pharmacokinetics, the clinical applications where they show promise, and the limitations of supplementation vs endogenous production.
• The “lean mass hyper-responder” phenomenon: The pattern of dramatic LDL elevation in some lean people on ketogenic eating, the contested interpretation of the cardiovascular implications, the Dave Feldman research community, and the state of the evidence.
• Fasting and the menstrual cycle in detail: Beyond what’s in the Game Plan, the deeper biology of how reproductive hormones interact with fasting, the cycle phase-specific protocols, and the case studies of female athletes using cyclical fasting.
• Fasting and reproduction: Conception, pregnancy, breastfeeding, postpartum recovery. The conservative position with the underlying evidence.
• Cold exposure and fasting: The intersection of two hormetic stressors. Brown fat activation, the timing question (combined vs sequential), the research base, and practical protocols.
• Exercise and fasting protocols in detail: Beyond what’s in Training Specificity, the deeper treatment of training in different fasted states, the periodisation of fasting and training together, and the specific implications for different sports.
• The supplement landscape during fasting: What’s worth taking, what’s actively harmful, what’s neutral, and the cost-benefit analysis. Substantial separation of marketing from evidence.
• The legal and medical context of clinical fasting: Why fasting therapy is underutilised in mainstream medicine, the regulatory environment, the practitioner liability concerns, and the path to broader clinical adoption.
• Buddhist and contemplative fasting practices: Deeper engagement with the traditions that combine fasting with meditation. The phenomenology of extended fasting in contemplative contexts. The intersection of physical and psychological effects.
• Fasting and longevity epidemiology: The natural experiments (Ramadan populations, Orthodox fasting populations, traditional populations with periodic scarcity), what we can learn from them, what we can’t.
• The history of fasting in medicine before pharmaceuticals: The 19th and early 20th century therapeutic fasting tradition that was largely displaced by the rise of pharmaceutical medicine. What was lost, what was rightly abandoned, what’s being rediscovered.

External Research Links

Aggregated research summaries:

• FoundMyFitness on autophagy: foundmyfitness.com/topics/autophagy
• FoundMyFitness on caloric restriction: foundmyfitness.com/topics/caloric-restriction
• FoundMyFitness on fasting: foundmyfitness.com/topics/fasting
• FoundMyFitness on time-restricted eating: foundmyfitness.com/topics/time-restricted-eating

Specific research findings:

• Time-restricted eating improves diabetes and heart disease: sciencedaily.com/releases/2019/12/191205141731.htm
• Fasting reduces chronic inflammation (Mount Sinai 2019): mountsinai.org/about/newsroom/2019/mount-sinai-researchers-discover-that-fasting-reduces-inflammation-and-improves-chronic-inflammatory-diseases

Practitioner resources:

• The Panda Lab at the Salk Institute: research output on circadian biology and time-restricted eating
• The Longo Lab at USC: research output on fasting, FMD, and longevity
• The Sinclair Lab at Harvard: research output on sirtuins and NAD+ (with commercial relationship caveats)
• The Verdin Lab at Buck Institute: research output on BHB signalling
• The Madeo Group at Graz: research output on spermidine and autophagy
• Christopher Palmer’s Brain Energy work: metabolic psychiatry framework
• Thomas Seyfried’s group at Boston College: cancer metabolism research
• Jason Fung’s Intensive Dietary Management Program: clinical fasting for diabetes and obesity